Lilly (Eli) (LLY) — insider trading
Health Care
Lilly (Eli) (LLY) has 13 reported SEC Form 4 insider transactions in our data, including 3 open-market sales among the most recent 13 (latest 2026-06-15).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-15 | Alvarez Ralph | Director | Grant / award / vesting | 11 | $1,129.35 | $12.4K | Form 4 |
| 2026-06-15 | Fyrwald J Erik | Director | Grant / award / vesting | 9 | $1,129.35 | $9.9K | Form 4 |
| 2026-06-15 | LUCIANO JUAN R | Director | Grant / award / vesting | 14 | $1,129.35 | $15.9K | Form 4 |
| 2026-06-15 | Sulzberger Gabrielle | Director | Grant / award / vesting | 4 | $1,129.35 | $5.0K | Form 4 |
| 2026-06-10 | Yuffa Ilya | Officer (EVP&Pres, LLY USA&Global Capab) | Open-market sale | 2,500 | $1,150.77 | $2.88M | Form 4 |
| 2026-05-18 | Alvarez Ralph | Director | Grant / award / vesting | 13 | $988.09 | $12.4K | Form 4 |
| 2026-05-18 | Fyrwald J Erik | Director | Grant / award / vesting | 10 | $988.09 | $9.9K | Form 4 |
| 2026-05-18 | LUCIANO JUAN R | Director | Grant / award / vesting | 16 | $988.09 | $15.9K | Form 4 |
| 2026-05-18 | Sulzberger Gabrielle | Director | Grant / award / vesting | 5 | $988.09 | $5.0K | Form 4 |
| 2026-05-06 | LILLY ENDOWMENT INC | Other | Open-market sale | 2,208 | $996.18 | $2.20M | Form 4 |
| 2026-05-06 | LILLY ENDOWMENT INC | Other | Open-market sale | 13,620 | $995.23 | $13.55M | Form 4 |
| 2026-04-20 | LUCIANO JUAN R | Director | Grant / award / vesting | 17 | $919.90 | $15.9K | Form 4 |
| 2026-04-20 | Sulzberger Gabrielle | Director | Grant / award / vesting | 5 | $919.90 | $5.0K | Form 4 |
Ask the chat about LLY's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Lilly (Eli) (LLY).
Last updated 2026-06-15 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.